Bone Abstracts

Background: There are no models for estimating risk of fracture in patients taking treatments for osteoporosis. Knowing a patient’s risk of fracture during treatment may help make future treatment decisions; therefore, the development of on-treatment fracture risk models is needed.Methods: To assess on-treatment fracture risk, the analysis included subjects who received denosumab (DMAb) 60 mg Q6 every 6 months for at least 1 year in either FREEDOM o...

Denosumab treatment is associated with low fracture incidence, sustained BMD increases, and reduced sCTX. The decrease in median sCTX is at the quantifiable limit (0.049 ng/ml) one month post-dose, remains low, and attenuates at the end of the 6-month dosing interval. Using 7 years of data from the FREEDOM study and its extension, we characterized changes in sCTX over time and the influencing factors. In the bone turnover marker and pharmacokinetic substudies, serum was collec...

Purpose: To test whether bisphosphonates for osteoporosis reduce the risk of breast cancer.Background: Observational studies and meta-analyses find that women taking bisphosphonates have about a 1/3rd reduction in risk of breast cancer as soon as 1 year of treatment. This is plausible because bisphosphonates have in vitro anti-tumor activity and high doses of zoledronate reduce recurrence in women with breast cancer. However, observational studi...